---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-012508"
form_type: "8-K"
ticker: "MBIO"
cik: "0001680048"
company_name: "MUSTANG BIO, INC."
filed_at: "2023-07-31T23:59:59+00:00"
generated_at: "2026-06-12T22:08:51.115993+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Mustang Bio closes amended asset sale to uBriGene for $6M upfront; cash runway into early 2024

## Summary
- Closed amended asset purchase agreement with uBriGene on July 28, 2023; received $6M upfront cash.
- Additional $5M contingent payment requires Mustang to raise $10M+ equity and landlord consent for lease assignment.
- Facility lease did not transfer; Mustang continues to occupy and manufacture MB-106; landlord has 30 days after CFIUS review.
- If lease not transferred within 120 days, uBriGene can request repurchase negotiations of transferred assets.
- Upfront proceeds and operating expense reductions extend cash runway into early 2024.

## SEC filing metadata
- accession: 0001558370-23-012508
- form_type: 8-K
- ticker: MBIO
- cik: 0001680048
- company_name: MUSTANG BIO, INC.
- filed_at: 2023-07-31T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 2.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1680048/000155837023012508/0001558370-23-012508-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1680048/000155837023012508/tmb-20230728x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-012508
- JSON: https://secwatch.observer/filing/0001558370-23-012508.json
- Plain text: https://secwatch.observer/filing/0001558370-23-012508.txt

## Key facts
- M&A Transactions
  MUSTANG BIO, INC. completed a disposition involving uBriGene (Boston) Biosciences, Inc. for $6,000,000 (the "Base Amount") (closed 2023-07-28).
  - Action: disposition
  - Counterparty: uBriGene (Boston) Biosciences, Inc.
  - Consideration: $6,000,000 (the "Base Amount")
  - Closing: 2023-07-28
  source text: detail below. Under the terms of the Amended Asset Purchase Agreement, on the Closing Date, uBriGene paid to the Company, as consideration for the Transaction, a base amount of $6,000,000 (the “ Base Amount ”). A contingent amount (the “ Contingent Amount ”) will be paid to the Company once the Company (i) completes an issuance of equity securities in an amount
  evidence_url: https://www.sec.gov/Archives/edgar/data/1680048/000155837023012508/0001558370-23-012508-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.